Facebook Linkedin RSS Twitter Youtube
Home 2023

Phase II clinical trials (Drug development)

Insilico’s AI Candidate for IPF Doses First Patient in Phase II
Artificial Intelligence

Insilico’s AI Candidate for IPF Doses First Patient in Phase II

Experimental Cancer Drug Slows Inflammation in Animal Models of Heart Disease
Drug Discovery

Experimental Cancer Drug Slows Inflammation in Animal Models of Heart Disease

Antibody Shows Promise against Autoimmune Diseases
Drug Discovery

Antibody Shows Promise against Autoimmune Diseases

Ultrasound Device Opens Blood-Brain Barrier to Treat Glioblastoma in Humans
Cancer

Ultrasound Device Opens Blood-Brain Barrier to Treat Glioblastoma in Humans

Generate:Biomedicines and MD Anderson Sign AI-Driven Protein Therapeutics for Cancer Deal
Artificial Intelligence

Generate:Biomedicines and MD Anderson Sign AI-Driven Protein Therapeutics for Cancer Deal

AACR News: Evaxion’s DNA-Based Personalized Cancer Immunotherapy EVX-02 Meets Phase I/IIa Endpoints
Cancer

AACR News: Evaxion’s DNA-Based Personalized Cancer Immunotherapy EVX-02 Meets Phase I/IIa Endpoints

Merck to Acquire Prometheus Biosciences for $10.8B
Drug Discovery

Merck to Acquire Prometheus Biosciences for $10.8B

Licit Activity: MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder
Drug Discovery

Licit Activity: MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder

Go Higher: Atai Life Sciences Is Moving the Dial on Psychedelic Medicine Clinical Trial Outcomes
Drug Discovery

Go Higher: Atai Life Sciences Is Moving the Dial on Psychedelic Medicine Clinical Trial Outcomes

Gossamer Stops Development of CNS Lymphoma Candidate after Two Patient Deaths, Partial Hold
Cancer

Gossamer Stops Development of CNS Lymphoma Candidate after Two Patient Deaths, Partial Hold

123...61Page 2 of 61
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.